% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

  • beachbumsoon325 beachbumsoon325 Nov 6, 2013 2:12 PM Flag

    Phase 3 STS enrollment

    In October 2013 at the annual meeting of the Sarcoma Alliance through Collaboration and Research (SARC) in New York, NY, William D. Tap, M.D., Section Chief, Sarcoma Oncology at Memorial Sloan-Kettering Cancer Center and Principal Investigator of the Phase 3 trial of TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma (Study 406) provided an update on enrollment. A total of 517 patients were enrolled in mid-October as reported by Dr. Tap on October 31, 2013; a total of 620 patients are expected to be enrolled.

    There are 96 centers for this trial. If half are at capacity, it would require roughly 2 new patients for each of the remaining centers to complete enrollment between now and Dec 31st.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.4784-0.0166(-3.35%)Jul 22 4:00 PMEDT